Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570479 · ClinicalTrials.gov registry record · Phase 1
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
A Phase 1 study, sponsored by Texas Retina Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00570479: Completed Phase 1 study, sponsored by Texas Retina Associates.
NCT00570479 is a Phase 1 study that has completed, run by Texas Retina Associates. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570479, a Phase 1 study, has completed, sponsored by Texas Retina Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Retisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP) following implantation in 60% of patients. Glaucoma filtering is required in over 30% of patients at 2 years. Anecortave acetate (AA) has been shown to reduce steroid induced elevated IOP. The purpose of this study was to evaluate the ability of prophylactic anterior juxtascleral depot administration of AA to prevent this Retisert induced elevated IOP.
Interventions
- DRUG anecortave acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
What the finished NCT00570479 record still lists
NCT00570479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which anecortave acetate is the first listed.
NCT00570479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00570479 about?
NCT00570479 is a clinical study titled "Prophylactic Anecortave Acetate in Patients With a Retisert Implant". Retisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP) following implantation in 60% of patients. Glaucoma filtering is required i...
What is the current status of trial NCT00570479?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00570479?
The interventions under investigation include: anecortave acetate (DRUG).
Who is sponsoring clinical trial NCT00570479?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00570479's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia